scholarly journals Parenteral iron therapy and phosphorus homeostasis: A review

2021 ◽  
Author(s):  
Kamyar Kalantar‐Zadeh ◽  
Tomas Ganz ◽  
Henry Trumbo ◽  
Melvin H. Seid ◽  
Lawrence T. Goodnough ◽  
...  
Keyword(s):  
Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

Parenteral Iron Therapy: A Single Institution's Experience Over a 5-Year Period

2005 ◽  
Vol 3 (6) ◽  
pp. 791-795 ◽  
Author(s):  
Christopher A. Laman ◽  
Scott B. Silverstein ◽  
George M. Rodgers
Keyword(s):  
Adverse Event ◽  
Adverse Events ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Iron Dextran ◽  
Serious Adverse Events ◽  
Exact Test ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy ◽  
Event Rates

Many patients require parenteral iron therapy for optimal correction of anemia, including cancer patients who require erythropoietic drugs. Available parenteral iron therapy options include iron dextran, iron gluconate, and iron sucrose. The purpose of this study is to summarize our institution's experience with parenteral iron therapy over a 5-year period, with a focus on comparative safety profiles. All patients receiving parenteral iron therapy over this period were included in the analysis. Chi-squared test and Fisher's exact test were used to compare the adverse event rates of each product. A total of 121 patients received 444 infusions of parenteral iron over this period. Iron dextran was the most commonly used product (85 patients) and iron sucrose was the least used (2 patients). Iron gluconate was used by 34 patients. Overall adverse event rates per patient with iron dextran and iron gluconate were 16.5% and 5.8%, respectively (P = .024). Premedication with diphenhydramine and acetaminophen before infusions of iron dextran reduced adverse event rates per infusion from 12.3% to 4.4% (P = .054). Test doses of iron dextran were used 88% of the time for initial infusions of iron dextran. All adverse events for all parenteral iron products were mild or moderate. There were no serious adverse events and no anaphylaxis was observed. Our results suggest that, if test doses and premedications are used, iron dextran is an acceptable product to treat iron deficiency.

Parenteral Iron Therapy

2018 ◽  
pp. 80-80
Author(s):  
Shirish Daftary ◽  
Munjal Pandya
Keyword(s):  
Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

scholarly journals Parenteral iron therapy exacerbates experimental sepsis Rapid Communication

2004 ◽  
Vol 65 (6) ◽  
pp. 2108-2112 ◽  
Author(s):  
Richard A. Zager ◽  
Ali C.M. Johnson ◽  
Sherry Y. Hanson
Keyword(s):  
Iron Therapy ◽  
Experimental Sepsis ◽  
Rapid Communication ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy

PARENTERAL IRON THERAPY IN PREGNANCY

1965 ◽  
Vol 72 (1) ◽  
pp. 89-93 ◽  
Author(s):  
D. W. Dawson ◽  
W. O. Goldthorp ◽  
D. Spencer
Keyword(s):  
Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy ◽  
In Pregnancy

Parenteral Iron Therapy

1964 ◽  
Vol 61 (6) ◽  
pp. 1053 ◽  
Author(s):  
PAUL R. MCCURDY
Keyword(s):  
Iron Therapy ◽  
Parenteral Iron ◽  
Parenteral Iron Therapy
Sign in / Sign up

Export Citation Format

Share Document